Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Piotroski F-Score: 6 (As of Jun. 29, 2026) — 20% Above Median


STU:08HH Shanghai Fosun Pharmaceutical (Group) Co Ltd STU:08HH
74 GF Score
Price €1.66
GF Value €2.12
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Piotroski F-Score?

Shanghai Fosun Pharmaceutical (Group) Co STU:08HH -2.38% 74 Piotroski F-Score is 6 as of Jun. 29, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates STU:08HH with a GF Score™ of 74/100 and a GF Value™ of €2.12 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 978 Drug Manufacturers companies, Shanghai Fosun Pharmaceutical (Group) Co ranks better than 79.24% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Fosun Pharmaceutical (Group) Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score or its related term are showing as below:

STU:08HH' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Shanghai Fosun Pharmaceutical (Group) Co was 8. The lowest was 4. And the median was 5.

Shanghai Fosun Pharmaceutical (Group) Co  (STU:08HH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanghai Fosun Pharmaceutical (Group) Co Piotroski F-Score Related Terms


Shanghai Fosun Pharmaceutical (Group) Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Piotroski F-Score Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 4.00 7.00 6.00

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 5.00 6.00 6.00

STU:08HH vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fosun Pharmaceutical (Group) Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score falls into.


STU:08HH
74GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd STU:08HH
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 113.164 + 98.234 + 102.733 + 109.294 = €423 Mil.
Cash Flow from Operations was 130.202 + 149.238 + 222.067 + 144.156 = €646 Mil.
Revenue was 1218.817 + 1181.564 + 1487.543 + 1264.25 = €5,152 Mil.
Gross Profit was 590.558 + 571.344 + 811.609 + 628.344 = €2,602 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(15055.413 + 14347.922 + 14127.728 + 14556.748 + 15433.021) / 5 = €14704.1664 Mil.
Total Assets at the begining of this year (Mar25) was €15,055 Mil.
Long-Term Debt & Capital Lease Obligation was €1,946 Mil.
Total Current Assets was €4,263 Mil.
Total Current Liabilities was €4,591 Mil.
Net Income was 78.762 + 100.063 + 99.589 + 97.582 = €376 Mil.

Revenue was 1319.677 + 1330.5 + 1332.058 + 1202.019 = €5,184 Mil.
Gross Profit was 630.015 + 639.57 + 613.782 + 574.197 = €2,458 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(14531.157 + 14795.185 + 14676.873 + 15407.151 + 15055.413) / 5 = €14893.1558 Mil.
Total Assets at the begining of last year (Mar24) was €14,531 Mil.
Long-Term Debt & Capital Lease Obligation was €1,811 Mil.
Total Current Assets was €4,394 Mil.
Total Current Liabilities was €4,530 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Fosun Pharmaceutical (Group) Co's current Net Income (TTM) was 423. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Fosun Pharmaceutical (Group) Co's current Cash Flow from Operations (TTM) was 646. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=423.425/15055.413
=0.02812444

ROA (Last Year)=Net Income/Total Assets (Mar24)
=375.996/14531.157
=0.02587516

Shanghai Fosun Pharmaceutical (Group) Co's return on assets of this year was 0.02812444. Shanghai Fosun Pharmaceutical (Group) Co's return on assets of last year was 0.02587516. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanghai Fosun Pharmaceutical (Group) Co's current Net Income (TTM) was 423. Shanghai Fosun Pharmaceutical (Group) Co's current Cash Flow from Operations (TTM) was 646. ==> 646 > 423 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1945.891/14704.1664
=0.13233603

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1810.612/14893.1558
=0.12157343

Shanghai Fosun Pharmaceutical (Group) Co's gearing of this year was 0.13233603. Shanghai Fosun Pharmaceutical (Group) Co's gearing of last year was 0.12157343. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=4262.772/4591.1
=0.92848598

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=4394.316/4529.816
=0.97008709

Shanghai Fosun Pharmaceutical (Group) Co's current ratio of this year was 0.92848598. Shanghai Fosun Pharmaceutical (Group) Co's current ratio of last year was 0.97008709. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanghai Fosun Pharmaceutical (Group) Co's number of shares in issue this year was 2638.865. Shanghai Fosun Pharmaceutical (Group) Co's number of shares in issue last year was 2637.096. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2601.855/5152.174
=0.50500138

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2457.564/5184.254
=0.4740439

Shanghai Fosun Pharmaceutical (Group) Co's gross margin of this year was 0.50500138. Shanghai Fosun Pharmaceutical (Group) Co's gross margin of last year was 0.4740439. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=5152.174/15055.413
=0.34221406

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=5184.254/14531.157
=0.35676815

Shanghai Fosun Pharmaceutical (Group) Co's asset turnover of this year was 0.34221406. Shanghai Fosun Pharmaceutical (Group) Co's asset turnover of last year was 0.35676815. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+0+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Fosun Pharmaceutical (Group) Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) has a Piotroski F-Score of 6 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #203 out of 978 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Shanghai Fosun Pharmaceutical (Group) Co's value of 6 is 20% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #203 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #203 out of 978 companies for Piotroski F-Score. This places Shanghai Fosun Pharmaceutical (Group) Co in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Shanghai Fosun Pharmaceutical (Group) Co's value of 6 is 20% above this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Shanghai Fosun Pharmaceutical (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.12, compared to a current price of €1.66 — trading 21.7% below its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Drug Manufacturers industry median of 5.00. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 74/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH), the current Piotroski F-Score is 6 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of €1.66 is trading 21.7% below its estimated GF Value™ of €2.12. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for STU:08HH:

  • Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
  • GF Value™: €2.12 vs. price of €1.66 (21.7% below fair value)
  • GF Score™: 74/100 with 10 warning signs
  • Industry Position: 20% above the Drug Manufacturers median (#203 of 978)

No single metric tells the full story. See the STU:08HH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
74GF Score

Get the complete analysis for STU:08HH

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.66
Price
€2.12
GF Value